Christopher R. Sansone - May 17, 2022 Form 4 Insider Report for InfuSystem Holdings, Inc (INFU)

Role
Director
Signature
/s/ Kevin Whitman, Attorney-in-Fact for Christopher R. Sansone
Stock symbol
INFU
Transactions as of
May 17, 2022
Transactions value $
$0
Form type
4
Date filed
5/17/2022, 05:00 PM
Previous filing
Feb 22, 2022
Next filing
Nov 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INFU Common Stock 25K May 17, 2022 Direct
holding INFU Common Stock 1.46M May 17, 2022 See F1
holding INFU Common Stock 228K May 17, 2022 See F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INFU Stock Option (right to buy) Award $0 +25K $0.00 25K May 17, 2022 Common Stock 25K $8.58 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are directly owned by Sansone Partners, L.P., a Delaware limited partnership. The Reporting Person is the managing member of (i) the general partner of this limited partnership and (ii) the investment manager of this limited partnership and, as such, may be deemed to indirectly beneficially own the shares held by this limited partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2 The reported securities are directly owned by Sansone Partners (QP), L.P., a Delaware limited partnership. The Reporting Person is the managing member of (i) the general partner of this limited partnership and (ii) the investment manager of this limited partnership and, as such, may be deemed to indirectly beneficially own the shares held by this limited partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 The stock option was issued with an exercise price equal to the Fair Value as defined by the 2021 Equity Plan, which is computed as the closing price of the Company's common stock reported on the NYSE American LLC on the date of grant.
F4 The option, representing the right to purchase 25,000 shares of InfuSystem Holdings, Inc. common stock, vests on the date of the 2023 annual shareholder meeting.